Collas Philippe, Håkelien Anne-Mari
Institute of Medical Biochemistry, University of Oslo, PO Box 1112 Blindern, 0317 Oslo, Norway.
Trends Biotechnol. 2003 Aug;21(8):354-61. doi: 10.1016/S0167-7799(03)00147-1.
The direct conversion of one differentiated cell type into another--a process referred to as transdifferentiation--would be beneficial for producing isogenic (patient's own) cells to replace sick or damaged cells or tissue. Adult stem cells display a broader differentiation potential than anticipated and might contribute to tissues other than those in which they reside. As such, they could be worthy therapeutic agents. Recent advances in transdifferentiation involve nuclear transplantation, manipulation of cell culture conditions, induction of ectopic gene expression and uptake of molecules from cellular extracts. These approaches open the doors to new avenues for engineering isogenic replacement cells. To avoid unpredictable tissue transformation, nuclear reprogramming requires controlled and heritable epigenetic modifications. Considerable efforts remain to unravel the molecular processes underlying nuclear reprogramming and evaluate stable of the changes in reprogrammed cells.
将一种分化细胞类型直接转化为另一种细胞类型——这一过程被称为转分化——对于产生同基因(患者自身的)细胞以替代患病或受损的细胞或组织将是有益的。成体干细胞展现出比预期更广泛的分化潜能,并且可能对它们所驻留组织以外的其他组织有贡献。因此,它们可能是有价值的治疗剂。转分化的最新进展涉及核移植、细胞培养条件的操控、异位基因表达的诱导以及从细胞提取物中摄取分子。这些方法为工程化同基因替代细胞开辟了新途径。为避免不可预测的组织转化,核重编程需要可控且可遗传的表观遗传修饰。仍需付出巨大努力来阐明核重编程背后的分子过程,并评估重编程细胞中变化的稳定性。